Preexisting morbidity profile of women newly diagnosed with breast cancer in sub-Saharan Africa: African Breast Cancer—Disparities in Outcomes study by Ayeni, O.A. et al.
C AN C E R E P I D EM I O LOG Y
Preexisting morbidity profile of women newly diagnosed
with breast cancer in sub-Saharan Africa: African Breast
Cancer—Disparities in Outcomes study
Oluwatosin A. Ayeni1,2 | Shane A. Norris1,2 | Maureen Joffe1,2 |
Herbert Cubasch2,3 | Moses Galukande4 | Annelle Zietsman5 |
Groesbeck Parham6 | Charles Adisa7 | Angelica Anele8 | Joachim Schüz9 |
Benjamin O. Anderson10 | Milena Foerster9 | Isabel dos Santos Silva11 |
Valerie A. McCormack9
1SAMRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg, Gauteng, South Africa
2Noncommunicable Diseases Research Division, Wits Health Consortium (PTY) Ltd, Johannesburg, Gauteng, South Africa
3Department of Surgery, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of Witwatersrand, Johannesburg, Gauteng,
South Africa
4Department of Surgery, Makerere University, Kampala, Uganda
5Department of Oncology, Windhoek Central Hospital, Windhoek, Namibia
6Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina
7Department of Surgery, Abia State University Teaching Hospital, Aba, Nigeria
8Department of Surgery, Federal Medical Centre, Owerri, Nigeria
9Section of Environment and Radiation, International Agency for Research on Cancer, (IARC/WHO), Lyon, France
10Fred Hutchinson Cancer Research Center, Seattle, Washington
11Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
Correspondence
Oluwatosin A. Ayeni, Non-communicable
Diseases Research Division Wits Health
Consortium, 31 Princess of Wales Terrace,
Parktown, Johannesburg, South Africa.
Email: oayeni@witshealth.co.za
Funding information
Cancer Association of South Africa (CANSA)
grant “Down-staging and improving survival of
breast cancer in South Africa”; NIH grant,
Grant/Award Number: NIH/R01-CA192627-
01; South African Medical Research Council
/University of the Witwatersrand Common
Epithelial Cancer Research Centre; Susan
G. Komen for the Cure Foundation,
Grant/Award Number: IIR 13264158
Abstract
The presence of preexisting morbidities poses a challenge to cancer patient care.
There is little information on the profile and prevalence of multi-morbidities in breast
cancer patients across middle income countries (MIC) to lower income countries (LIC)
in sub-Saharan Africa (SSA). The African Breast Cancer–Disparities in Outcomes
(ABC-DO) breast cancer cohort spans upper MICs South Africa and Namibia, lower
MICs Zambia and Nigeria and LIC Uganda. At cancer diagnosis, seven morbidities
were assessed: obesity, hypertension, diabetes, asthma/chronic obstructive pulmo-
nary disease, heart disease, tuberculosis and HIV. Logistic regression models were
used to assess determinants of morbidities and the influence of morbidities on
advanced stage (stage III/IV) breast cancer diagnosis. Among 2189 women, morbidity
Abbreviations: ABC-DO, Africa Breast Cancer—Disparities in Outcomes; BMI, body mass index; CD, communicable diseases; CI, confidence interval; COPD, chronic obstructive pulmonary
disease; ELISA, enzyme-linked immunosorbent assay; HICs, high-income countries; HIV, human immunodeficiency virus; LMICs, low and middle income countries; NCDs, non-communicable
diseases; OR, odds ratio; SEP, socioeconomic position; SSA, Sub-Saharan Africa; TNM, tumour, node, metastasis classification.
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prevalence was the highest for obesity (35%, country-specific range 15-57%), hyper-
tension (32%, 15-51%) and HIV (16%, 2-26%) then for diabetes (7%, 4%-10%),
asthma (4%, 2%-10%), tuberculosis (4%, 0%-8%) and heart disease (3%, 1%-7%). Obe-
sity and hypertension were more common in upper MICs and in higher socioeco-
nomic groups. Overall, 27% of women had at least two preexisting morbidities. Older
women were more likely to have obesity (odds ratio: 1.09 per 10 years, 95% CI
1.01-1.18), hypertension (1.98, 1.81-2.17), diabetes (1.51, 1.32-1.74) and heart dis-
ease (1.69, 1.37-2.09) and were less likely to be HIV positive (0.64, 0.58-0.71). Multi-
morbidity was not associated with stage at diagnosis, with the exception of earlier
stage in obese and hypertensive women. Breast cancer patients in higher income
countries and higher social groups in SSA face the additional burden of preexisting
non-communicable diseases, particularly obesity and hypertension, exacerbated by
HIV in Southern/Eastern Africa.
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1 | INTRODUCTION
Breast cancer is the most common malignancy and the leading cause
of cancer mortality in women worldwide. It is also the most common
cancer among women in sub-Saharan Africa (SSA),1 where the inci-
dence of this cancer is on the rise. These temporal changes form part
of an epidemiological transition occurring in SSA, characterised by
improved control of infectious diseases, ageing populations and
increasing prevalence of risk factors for non-communicable diseases
(NCD) due to economic advancement, urbanisation and lifestyle
modifications.2 These syndemics also result in multimorbidity (the
co-occurrence of two or more chronic comorbidities in one person)3
at the individual level, including in breast cancer patients.
Survival after breast cancer diagnosis is determined by patient
characteristics and disease-related factors such as stage at diagnosis
and breast cancer subtypes.4 In addition to these factors, studies
mostly originating from high-income countries (HICs) have shown that
several preexisting morbidities are associated with lower breast can-
cer survival, poorer overall outcomes and they also impact on treat-
ment recommendations and tolerance.5,6 These morbidities include
obesity, diabetes and insulin resistance, stroke, body composition and
mental health illnesses, that is, conditions that tend to be more com-
mon in older breast cancer patients.7
Preexisting chronic conditions have also been linked to stage at
cancer diagnosis, but the direction, degree and mechanisms of associ-
ations have not been consistent.8-10 The presence of preexisting mor-
bidities have been linked to increased risk of metastatic disease at
diagnosis,8 whereas links to earlier stage at diagnosis have been
reported in settings served by population-based breast cancer screen-
ing.11 Some studies also noted earlier stage at diagnosis in women
with hypertension,9,12 possibly arising from a “surveillance effect” (ie,
greater clinical scrutiny upon follow-up for hypertension/greater
opportunity to seek help during health system contacts for other
illnesses).
In the SSA setting, there is a paucity of data on the profile of pre-
existing morbidity profiles among breast cancer patients. Such profiles
are likely to differ across SSA countries at differing stages of eco-
nomic, developmental and lifestyle transitions, that is, different in SSA
middle income countries (MICs) from low income countries (LICs).13,14
Furthermore, in addition to the aforementioned conditions, the
setting-pertinent infectious disease of HIV needs to be taken into
account due to the ageing HIV-positive population successfully
treated with antiretroviral drugs.15 Establishing these SSA-specific
morbidity profiles of breast cancer patients will form a first step to
inform priorities for feasible management strategies in constrained
public health systems.
What's new?
Patients who get cancer on top of other health conditions
can be challenging to treat. Here, the authors analyze the
prevalence of chronic conditions in women newly diagnosed
with breast cancer in sub-Saharan Africa. They looked at
obesity, hypertension, diabetes, asthma/COPD, heart dis-
ease, tuberculosis, and HIV. Overall, 27% of the women had
2 pre-existing conditions. Obesity boosts breast cancer risk,
and obesity rates are rising among higher income groups.
HIV is a problem in the southern African populations, and
while HIV is not thought to contribute to breast cancer,
reports suggest that HIV-positive patients have poorer
prognosis.
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To date, we have investigated this morbidity profile among breast
cancer patients diagnosed at five hospitals in South Africa and found
that 44% of women had preexisting morbidities at diagnosis: 53%
were obese, 41% hypertensive, 22% HIV positive and 14% were dia-
betic. Multimorbidities were linked to older age and higher socioeco-
nomic status.12 In the present study, we broadened our perspective
to five SSA countries, including the upper MICs of South Africa and
Namibia, lower MICs of Zambia and Nigeria and LIC of Uganda. Our
aims were 3-fold: (a) to describe the prevalence and profile of pre-
existing chronic conditions and multimorbidity (at least two chronic
conditions in addition to breast cancer) in women newly diagnosed
with breast cancer in five countries in SSA; (b) to determine the
sociodemographic factors associated with individual chronic condi-
tions and multimorbidity and (c) to assess whether any of the individ-
ual chronic conditions or multimorbidity was associated with breast
cancer stage at diagnosis.
2 | METHODS
2.1 | Study design and study setting
Presence of preexisting chronic conditions and multimorbidity in
women newly diagnosed with breast cancer was examined within the
African Breast Cancer—Disparities in Outcomes (ABC-DO) study
cohort, a prospective multi-country hospital-based breast cancer
cohort in Southern (South Africa, Namibia and Zambia), Western
(Nigeria) and Eastern (Uganda) SSA countries.16 Incident breast cancer
patients were recruited at Windhoek Central Hospital, Namibia; Abia
State University Teaching Hospital and the Maranatha Private Clinic,
Aba and the Federal Medical Centre, Owerri, Nigeria; Chris Hani
Baragwanath Academic Hospital, Soweto, South Africa; Mulago Hos-
pital and the Uganda Cancer Institute, Kampala, Uganda; and the Can-
cer Diseases Hospital and University Teaching Hospital, Lusaka,
Zambia. The ABC-DO protocol was previously published.16
2.2 | Participants
Recruitment commenced from September through December 2014 in
most centres and was completed by April 2017 except in Zambia
(May 2016 through September 2017). Women ≥18 years of age with
a clinically/histologically confirmed newly diagnosed breast cancer
who provided written consent to participate in the study and provided
access to their medical records and tumour tissue were enrolled.
ABC-DO was approved by ethics committees at each recruitment
institution: IARC (IEC 13-19, IEC15-18), the London School of
Hygiene and Tropical Medicine (6459), University of Witwatersrand,
South Africa (M150345), Council for Science and Technology
(HS 1588) and the Ministry of Health and Social Services of Namibia
(17/3/3), University of Zambia Biomedical Research Ethics Committee
(004-08-15), Federal Medical Centre Owerri, Abia State University
Teaching Hospital and Uganda National Council for Science and
Technology (HS 1588). Our study was performed in accordance with
the Declaration of Helsinki.
The present analyses of preexisting morbidities were conducted
overall and by site-race group, with Namibian women separated into
black and non-black ethnic groups as these groups were different in
socioeconomic profile and stage distribution.17 Participants from
other countries were almost exclusively black women, 42 non-black
South Africans were excluded from the analysis as this group was too
small to analyse separately.
2.3 | Exposure and outcome data
The same face-to-face baseline questionnaire was utilised in all hospi-
tals except in South Africa where a preexisting survey instrument was
administered and harmonised to ABC-DO specifications. For this anal-
ysis, we included questions on age, self-identified ethnic group and
marital status. Educational level was categorised as primary education
or none and secondary education or higher. We grouped employment
into two categories, employed (highly skilled/skilled, employed in
South Africa) vs unemployed (unskilled, unemployed and retired in
South Africa). A score for socioeconomic position (SEP) was generated
from self-reported household facilities and possessions: home owner-
ship, flush toilet, indoor running water, vehicle, electricity, gas or elec-
tric stove, refrigerator, landline phone and a bed. A score of +1 was
allocated to each possession ranging from 0 (low) to 9 (high).
We examined the presence of seven chronic conditions: obesity,
hypertension, diabetes, heart disease, asthma/chronic obstructive pul-
monary disease (COPD), HIV infection and tuberculosis. The seven
conditions were included because of their known association with
breast cancer prognosis (obesity,18 diabetes,19 HIV4), their known
impact on treatment (eg, cardiotoxicity and worsening of hyperten-
sion20) and/or their known high prevalence in the least parts of SSA
where regular treatment may provide an avenue for early cancer
detection (eg, HIV and tuberculosis,21 COPD,22 hypertension and
heart disease23). Body weight and height were measured at enrol-
ment, and obesity was defined as a body mass index (BMI) ≥30.0 kg/
m2. Patients were asked if they had ever been treated for tuberculosis
and whether they had ever been diagnosed and treated with hyper-
tension, diabetes, heart disease, asthma/COPD (questionnaire on
chronic conditions collected provided as Supplementary material). HIV
infection (yes vs no/not known) was based on self-reports, with 90%
of the cohort (apart from South Africa) reporting the later; however,
there was a 97% agreement with clinical records among those
reported negative. In South Africa, HIV status was tested as part of
the diagnostic workup, using the enzyme-linked immunosorbent assay
by the National Health Laboratory Services. We defined mul-
timorbidity as having ≥2 of these seven chronic conditions, in addition
to breast cancer.
Breast cancer stage at diagnosis was determined using the Ameri-
can Joint Committee on Cancer (AJCC) TNM staging system24 and
categorised for analyses as early (Stages I and II) and advanced (Stages
III and IV).
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2.4 | Statistical methods
We described the pattern and prevalence of each chronic condition
by site-race group using Pearson's chi-squared and Fisher's exact
tests. We examined associations of sociodemographic factors with
each chronic condition and with multimorbidity (≥2 of these chronic
conditions in addition to the breast cancer) using logistic regression
analysis. Logistic regression was also used to examine whether each
chronic condition and multimorbidity were associated with advanced
stage breast cancer (Stages III and IV), as compared to early-stage
breast cancer (Stages I and II). Variables for which P values were <0.1
in bivariate analysis with advanced stage breast cancer were evalu-
ated and ORs were assessed adjusting for each covariate, HIV status,
age and country (as a proxy for level of health care). Analysis was per-
formed using Stata version 15 (StataCorp Ltd, TX).
3 | RESULTS
A total of 2189 women were included as follows: 720 (33%) from
South Africa, 478 (22%) (99 non-black and 379 black) from Namibia,
187 (9%) from Zambia, 382 (17%) from Nigeria and 422 (19%) from
Uganda (Table 1). The mean age at diagnosis was 51.7 ± 13.9, with
women from Zambia, Nigeria and Uganda (range of mean age
48.4-49.4 years) significantly younger than women from Namibia and
South Africa (range of mean age 52.5-57.1 years). Overall 62% of the
women had at least secondary school education with the non-black
Namibian (87%), South African (77%) and Nigerian (72%) women more
likely to have had at least secondary education compared to black
Namibian (49%), Zambian (47%) and Ugandan (42%) women. In keep-
ing with these low and middle income (LMIC) settings, most women
had low to medium SEP with higher SEP in non-black Namibia
TABLE 1 Characteristics of women newly diagnosed with breast cancer in sub-Saharan Africa, by country and race; African Breast Cancer—
Disparities in Outcomes study
Southern Africa (SA)
West Africa East Africa
South Africa
Namibia
non-Black Namibia Black Zambia Nigeria Uganda Total
N = 720 (%) N = 99 (%) N = 379 (%) N = 187 (%) N = 382 (%) N = 422 (%) N = 2189 (%)
Age in years, mean ± SD 54.5 ± 14.3 57.1 ± 12.4 52.5 ± 14.6 49.4 ± 14.2 48.8 ± 12.2 48.4 ± 12.6 51.7 ± 13.9
BMI (kg/m2) 31.7 ± 7.7 29.1 ± 6.8 26.4 ± 6.7 26.5 ± 6.3 26.4 ± 5.7 25.6 ± 4.6 28.1 ± 7.0
Marital status
Married 233 (32.4) 58 (58.6) 122 (32.2) 110 (58.8) 250 (65.4) 199 (47.2) 972 (44.4)
Not married 487 (67.6) 41 (41.4) 257 (67.8) 77 (41.2) 132 (34.6) 223 (52.8) 1217 (55.6)
Received secondary education
Yes 551 (76.5) 86 (86.9) 184 (48.5) 87 (46.5) 276 (72.3) 178 (42.2) 1362 (62.2)
No 169 (23.5) 13 (13.1) 195 (51.5) 100 (53.5) 106 (27.7) 244 (57.8) 827 (37.8)
Employment status
Employed 202 (28.1) 98 (99.0) 346 (91.3) 73 (39.0) 357 (93.5) 331 (78.4) 1407 (64.3)
Unemployed 518 (71.9) 1 (1.0) 33 (8.7) 114 (61.0) 25 (6.5) 91 (21.6) 782 (35.7)
SEP
Low (0–3) 273 (37.9) 0 (0.0) 166 (43.8) 67 (35.8) 161 (42.1) 249 (59.0) 916 (41.8)
Medium (4–6) 433 (60.1) 39 (39.4) 130 (34.3) 69 (36.9) 167 (43.7) 90 (21.3) 928 (42.4)
High (7–9) 14 (1.9) 60 (60.6) 83 (21.9) 51 (27.3) 54 (14.1) 83 (19.7) 345 (15.8)
Ever consumed alcohol?
No 565 (78.5) 37 (37.4) 185 (48.8) 123 (65.8) 178 (46.6) 225 (53.3) 1313 (60)
Yes 155 (21.5) 62 (62.6) 194 (51.2) 64 (34.2) 204 (53.4) 197 (46.7) 876 (40)
Ever smoked?
No 677 (94.0) 56 (56.6) 324 (85.5) 185 (98.9) 381 (99.7) 408 (96.7) 2031 (92.8)
Yes 43 (6.0) 43 (43.4) 55 (14.5) 2 (1.1) 1 (0.3) 14 (3.3) 158 (7.2)
Stage at diagnosis
Stages I and II 347 (49.6) 77 (77.8) 139 (36.7) 60 (40.3) 88 (25.1) 142 (36.5) 853 (41.3)
Stages III and IV 353 (50.4) 22 (22.2) 240 (63.3) 89 (59.7) 262 (74.9) 247 (63.5) 1213 (58.7)
Note: Missing values for covariates were as follows: stage at diagnosis (n = 132).
Abbreviations: BMI, body mass index; SEP, socioeconomic position.
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women. Smoking prevalence was low, ranging from <1% in Nigeria to
43% among the non-black Namibian women. Approximately 59% of
the women presented with advanced stage breast cancer overall (50%
in South Africa to 75% in Nigeria), with the exception of non-black
Namibian women where the majority presented with early-stage dis-
ease (78%) (Table 1).
3.1 | Prevalence of chronic conditions and
multimorbidity
Hypertension and obesity dominated as the most common chronic
conditions in breast cancer patients in each country, with hyperten-
sion ranking first in all countries except in South Africa where obesity
ranked as the most common preexisting chronic condition. HIV ranked
third prevalent in all countries except in non-black Namibians (where
asthma/COPD was in third rank) and in Nigeria (diabetes ranked
third). Diabetes was the fourth most prevalent chronic condition in
most countries except among the black Namibian women (tuberculo-
sis was fourth) and in Nigeria (heart disease was fourth) (Table 2).
Overall South Africa had the highest prevalence of HIV in the whole
cohort (26%) (Table 2) with 42% of the women <50 years of age
infected with HIV (Figure 1).
Twenty-seven percent of the women newly diagnosed with
breast cancer presented with multimorbidity (presence of ≥2
additional chronic conditions) ranging from 42% in South Africa to
11% in Uganda (Table 2). Percentages of women with multimorbidity
was the highest in South African women both under and over age
50, with 49% of the women ≥50 years presenting with multimorbidity
in addition to breast cancer. Women from lower MICs Zambia and
Nigeria and LIC Uganda had the least prevalence of multimorbidity in
both age groups (Figure 1).
With seven conditions included, of a possible 128 (27) morbidity
combinations, 57 combinations were present among the 2189 women
and only 16 combinations were present in at least 5 women. The pro-
file and prevalence of these combinations for the 11 most common
combinations in each population group is shown in Figure 2 (ie, no
preexisting morbidities and 10 combinations with at least one pre-
existing morbidities). Where multimorbidity was present, obesity and
hypertension were the dominant combination, affecting 15% of
Namibian non-black and 14% of South African women. The only other
combination affecting at least 5% of breast cancer patients in a given
group was obesity and HIV in South Africa.
3.2 | Determinants of chronic conditions
Associations of sociodemographic factors with each chronic condition
are presented in Table 3. In the mutually adjusted analysis of all coun-

































































































































































































































































































































(C) Women ≥50 years
NB = Non-black
F IGURE 1 The prevalence of preexisting chronic conditions at breast cancer diagnosis in the African Breast Cancer—Disparities in Outcomes
study, overall and by age at cancer diagnosis. Multimorbidity prevalence indicates the presence of two or more of the seven preexisting chronic
condition at the time of breast cancer diagnosis [Color figure can be viewed at wileyonlinelibrary.com]
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obese, hypertensive, diabetic and have heart disease and less likely
to be living with HIV. Of the three measures of socioeconomic sta-
tus, SEP was most frequently associated with the presence of a
chronic condition. Women with higher SEP (7-9 (high) and 4-6
(medium)) were more likely to be obese and diabetic compared to
women with low SEP (0-3). High SEP women were also more likely
to have hypertension compared to those with low SEP (OR: 1.89,
95% CI 1.33-2.59). Associations of age and SEP with the two
communicable diseases, tuberculosis and HIV, tended to be in the
opposite direction to those for the aforementioned NCDs. Notably,
women with medium SEP were less likely to have HIV compared to
the women with low SEP. Those employed were more likely to be
obese while level of education was not significantly associated with
any chronic condition except in Nigeria where those with secondary











































































































































































(A) South Africa (B) Namibia non-black
(C) Namibia black (D) Zambia
(E) Nigeria (F) Uganda
Ob = Obesity; Hy = Hypertension; Diab = diabetes; As = Asthma/COPD: Hrt = heart disease; Tb = tuberculosis;
F IGURE 2 Profile of the
combination of seven preexisting
morbidities among breast cancer
patients in the African Breast
Cancer—Disparities in Outcomes
study [Color figure can be viewed at
wileyonlinelibrary.com]
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Determinants of the presence of preexisting multimorbidities mir-
ror the associations mentioned earlier, particularly for the NCDs, as
the copresence of obesity and hypertension was the most prevalent
combinations. Adjusting for age and country site higher SEP compared
to low SEP was associated with greater risk for multimorbidity at
breast cancer diagnosis (Supplementary Table 1).
3.3 | Influence of preexisting morbidities on stage
at diagnosis
Among 2066 women with known stage at diagnosis, investigations of
whether preexisting morbidities affected stage at diagnosis are illus-















































































































1.3 .5 .7 1.5 2.5 4 7
F IGURE 3 Odds ratios of women being diagnosed with advanced stage breast cancer (stages III and IV) associated with each of the seven
chronic conditions examined by sub-Saharan Africa countries in the African Breast Cancer—Disparities in Outcomes study [Color figure can be
viewed at wileyonlinelibrary.com]
2166 AYENI ET AL.
analysis are shown in Table 4 and Supplementary Table 2. Most site-
specific associations were not significant or suggestive, with the fol-
lowing exceptions. Adjusting for age at diagnosis, obese women from
Zambia (OR: 0.36, 95% CI 0.16-0.78) and hypertensive women from
Nigeria (OR: 0.57, 95% CI 0.33-0.98) were less likely to be diagnosed
with advanced stage breast cancer compared to their country counter-
parts without these conditions. In contrast, among South African
women, those women who had tuberculosis were more likely to be
diagnosed with advanced stage breast cancer than those without such
a history (OR: 1.91, 95% CI 1.02-3.57). Nigeria, Zambian and Ugandan
women who were HIV infected were more likely to be diagnosed with
advanced stage breast cancer than their HIV-negative counterparts,
though these associations were not significant and were not present in
all settings (Figure 3).
Thus, meta-analytic estimates across all population groups
suggested no association of tuberculosis, asthma/COPD, diabetes and
HIV with stage at diagnosis, consistent with the pooled analyses in
Table 4. However for hypertension, in meta-analyses, there was a sug-
gestion of a 17% (−3% to 33%) relative reduction in advanced stage
breast cancer associated with having this condition, which increased
to a 35% (1%-55%) reduction in pooled analyses adjusted for HIV.
Similarly for obesity, the meta-analysis was suggestive of 12% (95%
CI −8% to 28%) reduced odds of advanced stage at diagnosis, which
became significant in pooled analyses (28% reduction (1%-48%).
Despite these individual conditions of obesity and hypertension being
the most common multimorbidity combination, the overall effect of
multimorbidity on advanced stage at cancer diagnosis was borderline
suggestive of a positive association (OR: 1.34, 95% CI 0.95-1.89)
(Table 4).
4 | DISCUSSION
4.1 | Summary of findings
In this large cohort of breast cancer patients in five SSA countries, the
prevalence of at least one of seven preexisting chronic conditions
(obesity, hypertension, diabetes, heart disease, asthma/COPD, HIV
infection and tuberculosis) was high (65%) and 27% of women had at
least two preexisting chronic conditions (multimorbidity). Obesity and
hypertension were the two most frequent conditions present, both
individually and as a combination among women with multi-
morbidities, particularly affecting older women and groups with higher
socioeconomic status both at the intracountry individual level and,
reflecting epidemiologic transitions, at national levels. HIV ranked
third in most countries except in non-black Namibian women and in
West African Nigeria. The management of breast cancer in SSA thus
needs to consider this high percentage of NCDs, alone or in combina-
tion with HIV. Nevertheless, none of the seven chronic conditions
investigated were positively associated with having advanced stage
breast cancer at diagnosis, with the exception of obesity and hyper-
tension, which was associated with having early stage breast cancer.
The latter findings point to an opportunity to further increase early
diagnosis, in an attempt to counterbalance any survival disadvantage
among these women.
4.2 | Major prevalent chronic conditions: in the
population as risk factors for breast cancer and impact
on prognosis
Multimorbidity prevalence closely tracked the wealth index of the
countries under investigation and the SEP scores of the women under
investigation. Women from higher MICs with more advanced
westernised lifestyle transitions had the greater multimorbidity bur-
den (South Africa (42%) followed by Namibia) than those from lower
middle-income Zambia and Nigeria and low-income Uganda. These
findings were in keeping with ranges of 14% to 68% reported from
other studies.12,25,26 With 27% of our patients presenting with mul-
timorbidity (≥2 chronic conditions), SSA is facing a significant chal-
lenge of multimorbidity comprising both infectious diseases combined
with the rapidly growing NCD prevalence as countries transition to
westernised lifestyles. Hypertension ranked as the most common
chronic condition in most countries except in South Africa where obe-
sity ranked first, ranging from 15% in LIC Uganda to 51% among MIC
non-black Namibian women. Hypertension is a public health challenge
in Africa with 46% of its population aged 25 years and over living with
hypertension.27 Hypertension might be positively linked to risk of
TABLE 4 Multiple logistic regression models of chronic conditions
and presence of multimorbidity (≥2 chronic conditions) as predictors
of advanced stage breast cancer (stages III and IV) in women newly
diagnosed with breast cancer in sub-Saharan Africa, African Breast
Cancer–Disparities in Outcomes study
Chronic conditions Odds ratio 95% CI P value
Obese
No 1.00 Reference .049
Yes 0.72 0.52-0.99
Hypertension
No 1.00 Reference .015
Yes 0.65 0.45-0.92
HIV
Negative 1.00 Reference .331
Positive 0.85 0.58-1.22
Any chronic condition
No 1.00 Reference .120
Yes 1.30 0.92-1.84
Multimorbidity
<2 chronic conditions 1.00 Reference .092
≥2 chronic conditions 1.34 0.95-1.89
Note: Multiple regression model (adjusted for age, country and HIV).
Obesity, hypertension, any chronic condition and multimorbidity were the
only variables significant at P < .01 on bivariate analysis and are evaluated
in the multivariate analysis. Variables significant at P < .05 shown in
boldface.
AYENI ET AL. 2167
breast cancer especially in postmenopausal women,28 hence its high
prevalence among our women is particularly worrying. More critically,
during the therapeutic phase, chemotherapy can worsen hypertension
and cause cardiomyopathy.29
Obesity, a known risk factor for breast cancer in postmeno-
pausal women,30 has also been associated with worse breast cancer
outcomes for women of all ages.18 Obesity was commonly reported
in our study though with high variation across countries in various
stages of lifestyle transition. South Africa has the highest preva-
lence with 57% of the women obese while Uganda had the lowest
prevalence (15%). The emerging prevalence of obesity in SSA has
been largely attributed to the rising empowerment of women, sed-
entary lifestyles, economic development and urbanisation,31 ulti-
mately leading to nutritional transition. Obesity at postmenopausal
ages is a driver of increasing breast cancer incidence rates, thus in
this instance the rising obesity rates are fuelling more cases with
poorer prognosis. Diabetes with prevalence ranging from 4% in
Uganda to 10% in South Africa is also a known risk factor for
breast cancer in postmenopausal women,32 it is also associated
with worse survival with up to an increased risk of 52% in overall
mortality.33
The high burden of HIV among particularly our southern African
women in our study is of continued concern with HIV now regarded
as a chronic infectious disease, though the general consensus is that
there is no significant link between HIV and risk of breast cancer;34
however, studies have reported poorer prognosis in HIV-positive
patients with breast cancer.4,35
4.3 | Determinants of chronic conditions
As expected, most chronic conditions were more prevalent in older
women, a finding consistent with previous studies in SSA.12,36 We
also found that women with higher SEP were more likely to present
with obesity, hypertension and diabetes in contrast to findings from
other mainly HIC studies where multimorbidity was more prevalent
at lower SEP.26,37,38 However our findings were consistent with
other studies from LMICs for multimorbidity,25 overweight/obesity,
hypertension and diabetes.36 These findings perhaps reflects
westernised lifestyle and dietary transitions first affecting higher
SEP groups with the capital needed to purchase and live modern
lifestyles.39
4.4 | Impact on stage
It is known that advanced cancer stage at diagnosis is affected by
chronic conditions;8-10 however, some studies have consistently dem-
onstrated earlier stage at diagnosis with chronic conditions.11,12,40 In
our study, we found no significant association between multimorbidity
and advanced stage at breast cancer diagnosis. Women who had
hypertension at diagnosis of breast cancer were more likely to have
early stage breast cancer, perhaps due to their regular access to the
health system facilities for other conditions.36,37 Our patients that
were obese were less likely to present with advanced stage breast
cancer, this is in contrast to studies suggesting that higher BMI is asso-
ciated with a more advanced stage of breast cancer at diagnosis.41,42
Our finding could be attributable to reverse causality given the 59% of
late-stage tumour in the cohort.
4.5 | Strengths and limitations
Our study benefitted from a diversity of countries across SSA, a wide
range of morbidities included, a strong SSA-perspective on the selec-
tion of morbidities, heterogeneity in sociodemographic factors, mea-
sured BMI, tested HIV in South Africa and a prospective design.
However, the sample was tertiary hospital-based patients, and many
breast cancer patients in SSA may never reach this level of the health
system. Further limitations were noted: most of these chronic condi-
tions were self-reported; hence, we could have underestimated the
prevalence of multimorbidity especially in women with lower SEP. In
SSA, low socioeconomic status is associated with lower access to care
and treatment43 and thus there could be lower rates of diagnosis of
these chronic conditions in women with lower SEP.
4.6 | Implications on therapeutic management
The implication of multimorbidity in women with breast cancer is
profound including the high cost of care44 and poor quality of life.45
Breast cancer patients with multimorbidity are less likely to receive
surgery,46 less likely to receive adjuvant chemotherapy,47 more
likely to receive a reduced dose and less likely to complete chemo-
therapy treatment when initiated,48 and less likely to initiate timely
radiotherapy after surgical treatment.49 Multimorbidity may cause
higher rates of adverse effects of treatment50 affecting overall goal
of care. It has been associated with an increased risk of
cardiotoxicity, immunosuppression during chemotherapy and radio-
therapy for HIV-positive women.51 Furthermore, at the health sys-
tem level, the management of multimorbidity is much more
complicated and demanding for the patients and the health system,
requiring an integrated approach and long-term care.52 To effec-
tively address these changing needs, countries in SSA require
detailed surveillance on chronic condition trends to assist in devel-
oping models of care appropriate for LMICs.
4.7 | Conclusion
There is a high prevalence of chronic conditions and multimorbidity in
our breast cancer patients and sociodemographic factors play a major
role in its determinants in SSA. With increasing life expectancy, the rap-
idly increasing multimorbidity burden in SSA is of great concern for its
under resourced healthcare services. SSA studies of the impact of these
morbidities on survival and therapeutic management are needed.
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